AutoWeb, Inc. (NASDAQ:AUTO) tinted gains of +3.66% (+0.12 points) to US$3.4. The volume of 0.09 Million shares climbed down over an trading activity of 113.28 Million shares. EPS ratio determined by looking at last 12 month figures is -5.21. Over the same time span, the stock marked US$14.3 as its best level and the lowest price reached was US$2.88. The corporation has a market cap of US$51.78 Million.
AutoWeb, Inc. (NASDAQ:AUTO)’s earnings per share has been growing at a 29.92 percent rate over the past 5 year when average revenue increase was noted as 16.3 percent. The return on equity ratio or ROE stands at -78.6 percent while most common profitability ratio return on investment (ROI) was -68.7 percent. The company’s institutional ownership is monitored at 51 percent. The company’s net profit margin has achieved the current level of -55.2 percent and possesses 27.4 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 3 think it is Hold. Recently, analysts have updated the overall rating to 2.75. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) is worth US$788.67 Million and has recently risen 3.63% to US$27.13. The latest exchange of 0.23 Million shares is below its average trading activity of 184.53 Million shares. The day began at US$26.42 but the price moved to US$26.42 at one point during the trading and finally capitulating to a session high of US$26.42. The stock tapped a 52-week high of US$37 while the mean 12-month price target for the shares is US$36.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 5.77, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 32.3%, it carries an earnings per share ratio of -1.49.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 3 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.6.